IRCT2014082510210N3
Completed
未知
assessment of the best luteal phase support (comparison of four protocols) for patients undergoing frozen-thawed embryo transfer in artificial cycle.
Vice chancellor for research of Shiraz University of Medical Sciences0 sites280 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vice chancellor for research of Shiraz University of Medical Sciences
- Enrollment
- 280
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •inclusion criteria:
- •unexplained infertility ? tubal factor? mild male factor ? POF ? sub fertility in pco field ? average age between 20\-40? normal uterine cavity
- •exclusion criteria:
- •women over 40 year? endometriosis stage III ?IV? Hydro salpinx ? severe male factor? ab normal uterine cavity ? failed embryo transfer cycle \=3
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI in Kernan in 2022IRCT20151004024335N5Kerman University of Medical Sciences288
Completed
Phase 3
Evaluation of luteal phase support on pregnancy rate in IUI cyclesfemale infertility.IRCT201011165181N2Chancellor for Research Of Tehran University of Medical Sciences260
Active, not recruiting
Phase 1
Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomized multicentre study. - Luteal Phase and IUIEUCTR2010-023867-17-BEniversity Hospital Leuven393
Completed
Phase 4
Luteal Support in Frozen-Thawed Embryo Transfer CyclesImplantation; PlacentaPregnancy LossFrozen EmbryoLuteal SupportLuteal Phase DefectAssisted ReproductionNCT03948022Centrum Clinic IVF Center151
Unknown
Phase 3
AKP-008 Clinical Study <Luteal phase support after in-vitro fertilization>uteal phase support after in-vitro fertilizationJPRN-jRCT2080222248ASKA Pharmaceutical Co., Ltd.